Evidence map›Paper›PMID 41069764›Full record

ReviewBioactive materials2026

Advancements in dual-targeting nanoparticle strategies for enhanced atherosclerosis therapy: Overcoming limitations of single-targeting approaches.

Can Yang, Liqing Mo, Guizhi Zhang, Yingxuan Dai, Binxiang Li, Zihan Tan, Yujie Guo, Shan Lu, Yi Hong, Hongliang He and 2 more

Abstract readReview
In one paragraph

Review in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Therapeutic Gases in Biomedicine: Updates on Nitric Oxide and Beyond.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. The research progress of LACC1.Frontiers in immunology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Can YangSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 430065, China.
Liqing MoSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 430065, China.
Guizhi ZhangSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 430065, China.
Yingxuan DaiSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 430065, China.
Binxiang LiSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 430065, China.
Zihan TanSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 430065, China.
Yujie GuoSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 430065, China.
Shan LuSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 430065, China.
Yi HongSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 430065, China.
Hongliang HeState Key Laboratory of Digital Medical Engineering, Jiangsu Key Laboratory for Biomaterials and Devices, School of Biological Sciences & Medical Engineering, Southeast University, Nanjing, 210009, China.
Hu YangJoint Department of Biomedical Engineering, Marquette University and Medical College of Wisconsin, Milwaukee, WI, 53226, United States.
Jianhua HeSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 430065, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atherosclerosis treatment remains challenging, particularly in terms of developing effective targeted drug delivery strategies to enhance therapeutic efficacy. As research advances, considerable attention has been paid to identifying specific cell types and subcellular organelles-based on molecular mechanisms, damage progression, and drug action-to design next-generation nanoformulations with greater precision. Dual-targeting nanoparticles, which integrate numerous targeting modalities, offer a promising approach to precise drug delivery to pathological plaque sites. By enabling sequential and synchronous navigation of the targeting moieties, these strategies offer greater control over drug delivery than conventional methods. In this review, we discuss the pathological process of atherosclerosis and examine the progress made in its treatment using rationally designed nanoparticles over recent decades. We critically evaluate the limitations of single-targeting strategies and explore potential areas for improvement. Further, we provide a comprehensive overview of the classification and core principles of dual-targeting methods, thereby evaluating their efficiency. Finally, we discuss the design and application of strategies that integrate targeting ligands with stimulus-responsive moieties or nanobiomimetic techniques, thereby demonstrating their potential to address ligand-based dual-targeting nanotechnology limitations.

Indexed as

AtherosclerosisDual-targeting deliveryMultifunctional nanoparticleNanobiomimetic techniquesStimulus-responsive moieties

Identifiers

PMID41069764
PMCPMC12506488

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.